UK group Healx is to collaborate with Boston Children’s Hospital and Barth Syndrome Foundation for Barth syndrome.
News
Auden Mckenzie and Waymade accused of illegal hydrocortisone agreement
The CMA has provisionally found that Auden Mckenzie and Waymademay entered into illegal anti-competitive agreements regarding the supply of hydrocortisone tablets.
Target PharmaSolutions & Novartis to launch real-world dermatology study
Target PharmaSolutions has named Novartis as its first TARGET-DERM registry industry partner.
BMS’ largest shareholder not in favour of Celgene deal
Bristol-Myers Squibb’s planned $74-billion purchase of Celgene has hit a significant obstacle after its largest institutional shareholder said it did not back the deal.
NHS to pilot new diabulimia service
NHS patients are set to receive therapy to “counteract the impact of harmful social media” as part of a new service designed to treat the rare eating disorder diabulimia.
Tremfya gets FDA approval in moderate-to-severe plaque psoriasis
Janssen has announced FDA approval of its novel drug Tremfya for adults with moderate-to-severe plaque psoriasis.
GW Pharmaceuticals announce quarterly financial results
GW Pharmaceuticals has reported revenue growth of 67.5% for the fourth quarter, driven by demand for Epidiolex.
Darolutamide’s FDA rolling submission completed
Orion and Bayer have announced the completion of the rolling submission of an NDA for darolutamide.
Experimental Parkinson’s therapy shows promise
A novel experimental drug could offer hope for restoring damaged brain cells in Parkinson’s patients.
MHRA gives Nuformix’ NXP001 studies the go-ahead
The MHRA has given Nuformix approval to commence human pharmacokinetics studies with NXP001 to further assess its potential for chemotherapy-induced nausea and vomiting.
Mental health information provided to patients improving, study finds
A new study has found that information being provided to patients about their rights under the Mental Health Act has improved.
Cell Medica given $8.7 million to develop cancer therapy
Cell Medica has been awarded a $8.7 million CPRIT grant to accelerate its CMD-502 cell therapy into clinical development.
ViiV Healthcare and Radboud team up for HIV drug targets
ViiV Healthcare has announced a collaboration with The Netherland’s Radboud University Medical Centre to identify new drug targets for HIV.
Lusutrombopag gets EU green light for liver disease
Marketing authorisation in the EU has been granted for Shionogi’s lusutrombopag in severe thrombocytopenia.
Unreasonable prescription costs leading to life-threatening asthma attacks
Asthma UK has revealed that people with asthma are rationing their medication due to prescription costs.
